Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice

Cancer Immunology, Immunotherapy

Volumn 50, Issue 1, 2001, Pages 31-40

  He, L ^a   Feng, H ^a   Raymond, A ^a   Kreeger, M ^a   Zeng, Y ^a   Graner, M ^a   Whitesell, L ^a   Katsanis, E ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

bcr abl; Dendritic cell; Peptide; Vaccine

Indexed keywords

BCR ABL PROTEIN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE FUSION; IMMUNITY; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION;

EID: 0035094066     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006680     Document Type: Article

References (31)

1. Bone marrow transplantation for chronic myelogenous leukemia
2. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells
3. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation
4. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF interferon-gamma
5. Specific human cellular immunity to bcr-abl oncogene-derived peptides
6. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
7. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein
8. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
9. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines
10. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
11. Related donor marrow transplant for chronic myeloid leukemia: Patient characteristics predictive of outcome
12. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
13. T cell growth factor: Parameters of production and a quantitative microassay for activity
14. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
15. Nonparametric estimation from incomplete observations
16. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity
17. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
18. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
19. 2 containing cell lysates
20. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program
21. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
22. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
23. Asymptotically efficient rank invariant procedures
24. Bone marrow-generated dendritic cells pulsed with a class i-restricted peptide are potent inducers of cytotoxic t lymphocytes
25. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
26. MHC ligands and peptide motifs: First listing
27. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
28. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes
29. Accessory cells, dendritic cells, or monocytes, are required for the lymphokine-activated killer cell induction from resting T cell but not from natural killer cell precursors
30. Clonal analysis of cytolytic T lymphocyte specificity. I. Phenotypically distinct sets of clones as the cellular basis of cross-reactivity to alloantigens
31. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia